Egetis Therapeutics (EGTX.ST) Stock Analysis & AI Equity Report
Egetis Therapeutics (EGTX.ST) overview
Egetis Therapeutics (EGTX.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Egetis Therapeutics reported revenue of SEK 62.4m and operating profit of SEK -347m; the year-end share price was 5.34 SEK and market capitalisation was SEK 1,966m. Egetis Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Egetis Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Egetis Therapeutics
Egetis Therapeutics is a Swedish pharmaceutical company focused on late-stage development and commercialization of treatments for rare diseases with high unmet medical need. Its lead product, Emcitate (tiratricol), is approved in the EU for MCT8 deficiency and is being developed for the US market. The company also develops Aladote for paracetamol overdose-related acute liver injury.
Generate the Egetis Therapeutics report
Egetis Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Egetis Therapeutics and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Egetis Therapeutics
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.